COVID-19 in patients with myasthenia gravis

Czech version

Authors: E. Ehler ^1,2; N. Medová ¹; Z. Wurst ¹; T. Peisker ³; P. Vaško ³; I. Štětkářová ³
Authors‘ workplace: Neurologická klinika, Pardubická, Krajská Nemocnice ¹; Fakulta zdravotnických studií, Univerzity Pardubice ²; Neurologická klinika 3. LF UK, a FN Královské Vinohrady, Praha ³
Published in: Cesk Slov Neurol N 2021; 84/117(4): 393-396
Category: Short Communication
doi: https://doi.org/10.48095/cccsnn2021393

Overview

Various infections can frequently lead to the exacerbation of myasthenia gravis (MG). COVID-19 infection characterized by lung impairment with respiration failure, massive inflammatory reaction and high mortality may lead to worsening of many neuromuscular disorders including MG. Published series of patients with MG and COVID-19 are considerably variable and differ in disease severity and selected therapeutic approach. In our group of 11 MG patients, substantial worsening was present in 3 patients, and in 4 there was a mild worsening of clinical myasthenic symptoms. In 3 patients, we used high doses of methylprednisolone intravenously, in 2 patients, the oral doses of prednisone were increased to 40 mg/60 mg a day, 1 patient was treated with intravenous immunoglobulin (2 g/kg), and 1 was treated with remdesivir. An 88-year-old woman was diagnosed with MG after COVID-19 infection. A 77-year-old man died after 6 days of mechanical ventilation. COVID-19 infection leads to an exacerbation of clinical symptoms in a large proportion of MG patients with ventilation disorder due to increased muscle fatigue and inflammatory changes in the lung parenchyma.

Keywords:

myasthenia gravis – COVID-19 – immunosuppression – exacerbation

Sources

1. Berlit P, Bösel J, Gahna G et al. „Neurological manifestations of COVID-19“ – a guideline of the German society of neurology. Neurol Res Pract 2020; 2: 51. doi: 10.1186/s42466-020-00097-7.

2. Anand P, Slama MCC, Kaku M et al. Covid-19 in patients with myasthenia gravis. Muscle Nerve 2020; 62 (6): E87–E88. doi: 10.1002/mus.27062.

3. Camelo-Filho AE, Silva AMS, Estephan EP et al. Myasthenia gravis and COVID-19: clinical characteristics and outcomes. Front Neurol 2020; 11: 1053. doi: 10.3389/fneur.2020.01053.

4. Dalakas MC. Inflammatory myopathies: update on diag- nosis, pathogenesis and therapies, and COVID-19 related implications. Acta Myol 2020; 39 (4): 289–301. doi: 10.36185/2532-1900-032.

5. Sharifian-Dorche M, Huot P, Osherova M et al. Neurological complications of coronavirus infection; a comparative review and lessons learned during the COVID-19 pandemic. J Neurol Sci 2020; 417: 117085. doi: 10.1016/j.jns.2020.117085.

6. Moschella P, Roth P. Isolated COVID-19 infection precipitates myasthenia gravis crisis: a case report. Clin Pract Cases Emerg Med 2020; 4 (4): 524–526. doi: 10.5811/cpcem.2020.9.49049.

7. Paliwal VK, Garg RK, Gupta A et al. Neuromuscular presentations in patients with COVID-19. Neurol Sci 2020; 41 (11): 3039–3056. doi: 10.1007/s10072-020-047 08-8.

8. Sriwastava S, Tandon M, Kataria S et al. New onset of ocular myasthenia gravis in a patient with COVID-19: a novel case report and literature review. J Neurol 2020; 268 (8): 2690–2696. doi: 10.1007/s00415-020-10 263-1.

9. Huber M, Rogozinski S, Puppe W et al. Postinfectious onset of myasthenia gravis in a COVID-19 patient. Front Neurol 2020; 11: 576153. doi: 10.3389/fneur.2020.576 153.

10. Kalita J, Tripathi A, Dongre N et al. Impact of COVID-19 pandemic and lockdown in a cohort of myasthenia gravis in India. Clin Neurol Neurosurg 2021; 202: 106488. doi: 10.1016/j.clineuro.2021.106488.

11. Costamagna G, Abati E, Bresolin N et al. Management of patients with neuromuscular disorders et the time of the SARS-CoV-2 pandemic. J Neurol 2020; 268 (5): 1580–1591. doi: 10.1007/s00415-020-10149-2.

12. Losy J. SARS-CoV-2 infection: symptoms of the nervous system and implications for therapy in neurological disorders. Neurol Ther 2021; 10 (1): 31–42. doi: 10.1007/s40120-020-00225-0.

13. Dalakas MC. Progress in the therapy of myasthenia gravis: getting closer to effective targeted immunotherapies. Curr Opin Neurol 2020; 33 (5): 545–552. doi: 10.1097/WCO.0000000000000858.

14. Ramaswamy SB, Govindarajan R. COVID-19 in refractory myasthenia gravis – a case report of successfull outcome. J Neuromuscul Dis 2020; 7 (3): 361–364. doi: 10.3233/JND-200520.